Please login to the form below

Not currently logged in
Email:
Password:

Innovate UK supports AI drug discovery project worth £1m

Project aims to use deep learning to utilise complex medicine data

AI

The UK’s innovation agency is backing research to develop artificial intelligence in drug discovery as part of a £1m project.

Innovate UK's funding will facilitate the Medicines Discovery Catapult's collaboration with software solutions company Optibrum and University of Cambridge spin-out Intellegens.

The companies will work together for the next two years, aiming to provide better insights into how a drug interacts with the body.

By homing in on Intellegens’ deep learning methods, the partners are hoping to create a next generation platform that will better predict the absorption, distribution, metabolism, excretion and toxicity (ADMET) of new drug candidates.

Ben Pellegrini, chief executive of Intellegens, said: “Intellegens is extremely excited to be part of this collaboration and looks forward to applying our novel deep learning techniques to help build a next generation platform to improve the drug discovery process.”

The new platform will be based off of Optibrium’s StarDrop and will look to improve the scope and reliability of drug design parameters, currently inaccessible or unavailable, for the first time.

Matthew Segall, chief executive of Optibrium, said: “We will apply cutting edge deep learning methods and new data to address important challenges in drug optimisation.

“The funding from Innovate UK is important validation of our project team’s expertise and the impact it will have on the industry’s efficiency and productivity.”

Currently 90% of drugs fail somewhere between phase 1 trials to regulatory approval, which means pharmaceutical companies are often incurring high drug developmental costs, but this new initiative hopes to improve this.

Professor John Overington, chief informatics officer of the Medicines Discovery Catapult, said: “At Medicines Discovery Catapult we apply innovation, working alongside UK SMEs to drive the development and adoption of new approaches for the discovery and early development of new medicines. This collaborative R&D activity will allow us to do just that and the grant from Innovate UK represents an important milestone for the advancement of informatics and data science.”

Article by
Gemma Jones

19th September 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics